Authors' recommendations: Hepatocellular carcinoma is the most common type of liver cancer. Most cases of hepatocellular carcinoma are caused by cirrhosis, where the liver is damaged and scarred because of excessive alcohol intake, long term infection with hepatitis B or C, or fatty liver disease. It is more common in men than women and typically affects older people. Lenvatinib is a new type of drug that is taken as a capsule by mouth. Some studies have suggested that lenvatinib may help patients with hepatocellular carcinoma when other treatments are no longer working. Another study is trying to show how well it works and that it is safe to use. If licensed for use in the UK, lenvatinib could be a new first line treatment option for people with hepatocellular carcinoma.

Project Status: Completed

Year Published: 2016

URL for published report: http://www.hsric.nihr.ac.uk/topics/lenvatinib-lenvima-for-unresectable-hepatocellular-carcinoma-first-line/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)